Evidence map›Paper›PMID 34325595›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2021

Design and characterisation of piperazine-benzofuran integrated dinitrobenzenesulfonamide as

Vallabhaneni S Murthy, Yasinalli Tamboli, Vagolu Siva Krishna, Dharmarajan Sriram, Siddique Akber Ansari, Abdullah A Alarfaj, Abdurahman H Hirad, Vijayaparthasarathi Vijayakumar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Vallabhaneni S MurthyCentre for Organic and Medicinal Chemistry, Department of Chemistry, School of Advanced Sciences, VIT University, Vellore, India.
Yasinalli TamboliCentre for Organic and Medicinal Chemistry, Department of Chemistry, School of Advanced Sciences, VIT University, Vellore, India.ORCID https://orcid.org/0000-0002-5161-0170
Vagolu Siva KrishnaMedicinal Chemistry and Antimycobacterial Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Hyderabad, India.
Dharmarajan SriramMedicinal Chemistry and Antimycobacterial Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Hyderabad, India.
Siddique Akber AnsariDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Abdullah A AlarfajDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Abdurahman H HiradDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Vijayaparthasarathi VijayakumarCentre for Organic and Medicinal Chemistry, Department of Chemistry, School of Advanced Sciences, VIT University, Vellore, India.
King Saud University · SAVellore Institute of Technology University · INBirla Institute of Technology and Science, Pilani · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular hybridisation of four bioactive fragments piperazine, substituted-benzofuran, amino acids, and 2,4-dinitrobenzenesulfonamide as single molecular architecture was designed. A series of new hybrids were synthesised and subjected to evaluation for their inhibitory activity against

Indexed as

Drug DesignAmidesAntitubercular AgentsBenzenesulfonatesBenzofuransCell Line, TumorDrug Screening Assays, AntitumorHumansMicrobial Sensitivity TestsMolecular Docking SimulationMycobacterium tuberculosisPiperazineSpectrum AnalysisAmidesAntitubercular AgentsBenzenesulfonatesbenzofuranBenzofuransdinitrobenzenesulfonic acidPiperazine2,4-dinitrobenzene sulphonamideamino acidanti-TBhybridisationPiperazine-benzofuran

Identifiers

PMID34325595
PMCPMC8330757
OpenAlexW3184783357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.